Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 3, 2026

Development and Optimization of A Human Hepatocellular Carcinoma Patient-Derived Organoid Model for Potential Target Identification and Drug Discovery
07:25

Development and Optimization of A Human Hepatocellular Carcinoma Patient-Derived Organoid Model for Potential Target Identification and Drug Discovery

Published on: August 18, 2023

Small HCCs identified by screening.

Petr Pancoska1, Massimo De Giorgio, Stefano Fagiuoli

  • 1Center for Clinical Pharmacology, University of Pittsburgh, Pittsburgh, PA, USA.

Digestive Diseases and Sciences
|April 6, 2011
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mortality Attributable to Hepatitis B and C in Italy, Romania, and Spain, 2022 Estimates.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Outcomes of Y90-radioembolization as downstaging to liver transplantation in patients with hepatocellular carcinoma and tumoral portal vein thrombosis.

Hepatology (Baltimore, Md.)·2026
Same author

HALP Score in Predicting Post-Liver Transplant Outcomes in Patients with Hepatocellular Carcinoma.

Journal of clinical medicine·2026
Same author

Combined treatment with vitamin K2 and albumin inhibits growth in hepatocellular carcinoma cells by promoting differentiation and apoptosis.

Molecular biology reports·2026
Same author

Durvalumab-Tremelimumab in Advanced Hepatocellular Carcinoma: Real-World Data From the LOR-HCC (Lombardy Real-World HCC Group).

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

Evaluation of Italian clinical practice for preventing HBV recurrence post-LT: a Delphi panel study.

Minerva gastroenterology·2026
Same journal

Upward Mobility: How Mobile Endoscopy Revolutionized Endoscopic Practice in the Developing World.

Digestive diseases and sciences·2026
Same journal

Hematologic and Inflammatory Biomarker-Based Prognostic Assessment in Acute Pancreatitis: The Role of CRP, Procalcitonin, and CRP/Albumin Ratio.

Digestive diseases and sciences·2026
Same journal

Prevalence and Impact of Protein-Calorie Malnutrition in Hospitalized Patients with Steatotic Liver Disease.

Digestive diseases and sciences·2026
Same journal

Development and Validation of a Crotonylation-Related Prognostic Risk Model for Cholangiocarcinoma Based on Integrative Transcriptome Analysis.

Digestive diseases and sciences·2026
Same journal

Cardiac Arrests During Inpatient Gastrointestinal Endoscopic Procedures: A United States Nationwide Assessment.

Digestive diseases and sciences·2026
Same journal

Standardizing Transition of Care for Adolescents with Inflammatory Bowel Disease: The Need for a Unified Approach.

Digestive diseases and sciences·2026
See all related articles

Serum tests like GGTP and ALKP can help identify different subtypes of early-stage hepatocellular carcinoma (HCC). These markers, along with AFP and albumin, show distinct patterns as HCC tumor mass increases.

Area of Science:

  • Hepatocellular Carcinoma (HCC) research
  • Biomarker discovery in oncology
  • Liver function testing

Background:

  • Early diagnosis of HCC is crucial for patient survival.
  • Surveillance radiology is key for early HCC detection.
  • Complementary serum biomarkers are needed for HCC diagnosis.

Purpose of the Study:

  • To evaluate liver function parameters in HCC patients diagnosed via surveillance.
  • To analyze trends in serum markers related to tumor mass.
  • To identify distinct HCC tumor mass phenotypes using serum markers.

Main Methods:

  • Analysis of baseline liver function parameters in 231 HCC patients.
  • Patients diagnosed via surveillance radiology.
  • Correlation of serum markers (GGTP, AFP, ALKP, albumin, bilirubin) with tumor mass and each other.

More Related Videos

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)

Published on: May 10, 2016

Related Experiment Videos

Last Updated: Jun 3, 2026

Development and Optimization of A Human Hepatocellular Carcinoma Patient-Derived Organoid Model for Potential Target Identification and Drug Discovery
07:25

Development and Optimization of A Human Hepatocellular Carcinoma Patient-Derived Organoid Model for Potential Target Identification and Drug Discovery

Published on: August 18, 2023

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)
11:38

High Content Screening Analysis to Evaluate the Toxicological Effects of Harmful and Potentially Harmful Constituents (HPHC)

Published on: May 10, 2016

Main Results:

  • GGTP levels increased linearly with small HCC tumor mass.
  • AFP levels elevated with larger HCC tumor mass; ALKP elevated with small and large tumors.
  • Interrelationships between markers (AFP-GGTP, albumin-bilirubin, ALKP-bilirubin) identified tumor phenotypes.
  • Bilirubin and AFP relationship suggests HCC growth and liver factors are interdependent.

Conclusions:

  • Small HCCs exhibit phenotypic subgroups.
  • Serum GGTP and ALKP increase with tumor mass.
  • Albumin levels decrease in many patients as HCC tumor mass increases.